Major players in the cell therapy technologies market are Thermo Fisher Scientific, Merck, MaxCyte, Lonza Group, Sartorius, Terumo BCT, Fresenius Medical Care AG & Co. KGaA, Avantor Inc. , Miltenyi Biotec, STEMCELL Technologies Inc.
New York, Feb. 11, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Cell Therapy Technologies Global Market Report 2022" – https://www.reportlinker.com/p06229201/?utm_source=GNW
, Beckman Coulter, Danaher, Becton Dickinson and Company and GE Healthcare.
The global cell therapy technologies market is expected to grow from $2.96 billion in 2021 to $3.52 billion in 2022 at a compound annual growth rate (CAGR) of 19.0%. The growth is mainly due to an increase in investments in cell therapies and the growth in research and development for cell therapy. The market is expected to reach $6.35 billion in 2026 at a CAGR of 15.9%.
The cell therapy technologies market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies.Cell therapy is a type of treatment used to inject active cells into the body of a patient for treating some disorders.
This therapy seeks to treat diseases by altering certain sets of cells. In this technique, cells, which originate from the patient or a donor are modified outside the body and then injected into the patient.
The main types of products in cell therapy technologies are consumables, equipment, systems & software and is applied on the different type of cells including t-cells, stem cells, and other cells.Stem cells are special human cells that can become almost any type of cell in the human body.
This can range from brain cells to muscle cells and is also used to fix damaged tissues. The different processes include cell processing, cell preservation, distribution, and handling, process monitoring and quality control and used in various sectors such as life science companies, research institutes.
Increasing investments by the government in cell-based research contributed to the growth of the global cell therapy technologies market.Governments are increasingly investing in research activities for developing therapies for diseases such as cancer, cardiovascular disease (CVD), and others.
For instance, in November 2019, the Australian government released $150 million, over 10 years, for The Stem Cell Therapies Mission.The funding was obtained by Medical Research Future Fund (MRFF), to support Australian researchers to deliver new therapies.
Moreover, in August 2019, Newcastle University spin-out Atelerix, pioneers in the storage and transport of cells at room temperature, were awarded a grant of £267,000 ($292,087) from Innovate UK, with collaborators Rexgenero and the cell and gene therapy catapult. Thus, the upsurge in government investments in cell-based research boosted the demand for the cell therapy technologies market in the historic period.
High costs associated with cell therapy is expected to restrain the market in the forecast period.The pressure to contain costs and demonstrate value is widespread.
Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy.
For example, cell therapies, especially gene-editing cell therapies such as CAR-T therapy highly expensive.The two first CAR T-cell therapies, Kymriah and Yescarta, have been given price tags of $475,000 and $373,000 respectively, in the USA, with similar pricing in Europe.
Thus, the high cost of cell therapy is restraining the growth of the market.
Strategic collaborations and partnerships between the industry players are gaining popularity in the cell therapy technologies market.Major companies are collaborating and partnering with other companies to developing new technologies in cell therapy areas for the treatment of a variety of diseases.
For instance, in August 2020, IsoPlexis Corporation, USA-based collaborated with Lonza, a Switzerland-based chemicals and biotechnology company to enable the next generation of precision cell therapy manufacturing. In another instance, in July 2020, Hitachi, Ltd., a Japan-based provider of a broad range of solutions including automated cell culture technologies to pharmaceutical companies in the area of cell therapy and regenerative medicine industry collaborated with ThinkCyte, Inc., a Japan-based biotechnology company to focus on developing artificial intelligence (AI)-driven cell analysis and sorting system.
In March 2020, Danaher Corporation, a USA-based company that designs, manufactures, and markets professional, medical, industrial, and commercial products, and services acquired General Electric (GE) biopharma business for $21.4 billion. The biopharma business was a part of the GE life sciences division that offered software and equipment used in biopharmaceutical research. The acquisition is expected to expand Danahe life sciences business. General Electric Company is an American company that operates in four industrial segments: aviation, power, renewable energy, and healthcare globally.
North America was the largest region in the cell therapy technologies market in 2021.Asia Pacific is predicted to record fastest growth over the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cell therapy technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
Read the full report: https://www.reportlinker.com/p06229201/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
The dollar traded flat and the euro weakened on Friday after a higher-than-expected Thursday readout of U.S. consumer prices that amped up investor expectations of interest rate hikes. Comments from St. Louis Federal Reserve President James Bullard on Thursday unleashed a wave of bets on aggressive rate increases after the Labor Department said that in the 12 months through January, the CPI jumped 7.5% – the biggest year-on-year increase since February 1982. Bullard told Bloomberg he'd like to see 100 basis points of hikes by July, adding that he had become “dramatically” more hawkish.
The 'buy now, pay later' company issues a fiscal third-quarter revenue forecast below analysts' expectations.
Big companies will pour big bucks into the metaverse, but experts say there is room for small-business owners too. Here's what they should be doing now to prepare.
KUALA LUMPUR (Reuters) -Capital A Bhd , which owns Malaysia's flagship budget airline AirAsia, is forming an independent board for its aviation arm while mulling a separate listing of the business as the market recovers, its chief said on Friday. Capital A Chief Executive Tony Fernandes told reporters in a virtual briefing that all companies under the group, including the airline, would be managed independently, and that the parent group intends for the airline to list. "I think that's up to the board at the right time when they think they need to list and raise capital independently, but definitely from Capital A's board, that is very much a plan," he said.
A California regulatory agency said it has filed a lawsuit against Tesla, alleging racial discrimination and harassment at the electric-vehicle maker.
BENGALURU (Reuters) -Shares of Zomato Ltd tumbled up to 8.4% on Friday after the Indian food delivery firm posted tepid sequential gross order value growth (GOV) in the third quarter as more people opted to dine out following the easing of pandemic curbs. After market close on Thursday, Zomato said its third-quarter GOV – the total monetary value of all food delivery orders – surged 84.5% from a year ago, but sequentially it rose only 1.7% as restrictions on dining out were lifted. Brokerage Jefferies cut Zomato's gross merchandise value forecast for full year 2022-26 by 4%-9%, and said the past two quarters signal how unpredictable this business (and probably the internet sector) is likely to be.
(Bloomberg) — Naturgy Energy Group SA shares fell the most in two years as investors digested a plan by Spain’s largest distributor of natural gas to split into two listed companies, separating the infrastructure business from its energy operations.Most Read from BloombergThe Housing Boom May Be About to Go BustFed Doesn’t Yet Favor a Half-Point Hike or an Emergency MoveThe Housing Party Is Starting to Wind DownTreasuries Sink With Stocks as Rate Bets Repriced: Markets WrapU.S. Inflation Charge
(Bloomberg) — Lumber is on a tear again, bringing back the specter of increasing construction costs. Most Read from BloombergThe Housing Boom May Be About to Go BustThe Housing Party Is Starting to Wind DownPeloton’s Famous Instructors, Who Can Make Upwards of $500,000 a Year, Escape LayoffsMusk Looks Increasingly Isolated as Automakers Embrace LidarAmazon Is Raising Base Salary Cap to $350,000 From $160,000Lumber futures have recouped recent losses and risen by the exchange maximum of $45 for
Stocks nudged higher in early trade Friday as investors weighed how aggressive the Federal Reserve will be in tightening policy a day after another hotter-than-expected inflation reading. The Dow Jones Industiral Average was up 50 points, or 0.1% at 35,292,while the S&P 500 rose 0.1% to 4,506.63 and the Nasdaq Composite shed 0.1% to 14,166.
Berkshire Hathaway's quarterly filing of its equity holdings is expected on Monday. Buffett has taken a cautious approach during the pandemic.
Mercedes-Benz Cars & Vans expects an adjusted earnings before interest and taxes (EBIT) of 14 billion euros ($15.9 billion) in 2021 and sees supply chain headwinds persisting into 2022, it said on Friday. The luxury carmaker predicted an adjusted return on sales of 12.7% in the full year, beating its own guidance of 10%-12% as the jump in electric vehicle sales made up for supply chain troubles, it said as it released preliminary results. But it expects high raw material prices and semiconductor shortages to prevent it meeting strong demand for its products this year, Chief Financial Officer Harald Wilhelm told a call with analysts.
Industrials company Nordson Corp. will join the S&P 500 index, replacing Xilinx Inc., S Indices said late Thursday. PDC Energy Inc. will replace Nordson in the SP MidCap 400 index, the provider said. The changes are effective Feb. 15. Advanced Micro Devices Inc. is buying Xilinx in a deal expected to be completed around Feb. 14. Shares of Nordson rose 1.4% in the extended session after ending the regular trading day down 2.2%.
Sociedad Quimica Y Minra shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
(Bloomberg) — Sign up for the New Economy Daily newsletter, follow us @economics and subscribe to our podcast.Most Read from BloombergThe Housing Boom May Be About to Go BustThe Housing Party Is Starting to Wind DownPeloton’s Famous Instructors, Who Can Make Upwards of $500,000 a Year, Escape LayoffsMusk Looks Increasingly Isolated as Automakers Embrace LidarByron Allen Says He’s Preparing Bid for NFL’s Denver BroncosA growing number of European Central Bank policy makers are losing faith in th
Twitter earnings were in focus after a mixed bag of results from social media peers Meta Platforms, Snap, and Pinterest last week.
Cloudflare stock reversed down after Q4 profit met views while revenue topped estimates. The 2022 revenue guidance of NET stock came in above views.
After soaring past $45,000, the largest cryptocurrency by market cap plummeted to under $44,000 later in the day; ether and other major altcoins were in the red.
(Bloomberg) — Bank of Canada Governor Tiff Macklem indicated the future path of interest-rate increases will depend in part on whether the nation’s businesses ramp up investment as the economy emerges from the pandemic.Most Read from BloombergThe Housing Boom May Be About to Go BustThe Housing Party Is Starting to Wind DownPeloton’s Famous Instructors, Who Can Make Upwards of $500,000 a Year, Escape LayoffsMusk Looks Increasingly Isolated as Automakers Embrace LidarAmazon Is Raising Base Salary
Chemours Co. stock fell more than 4% in the extended session Thursday after the chemicals company reported an adjusted profit below expectations. Chemours said it earned $233 million, or $1.40 a share, in the quarter, compared with $19 million, or 11 cents a share, in the year-ago quarter. Adjusted for one-time items, Chemours earned 81 cents a share. Sales rose 18% to $1.6 billion. Analysts polled by FactSet expected the company to report adjusted earnings of 89 cents a share on sales of $1.6 b
Analysts are expecting Baidu’s earnings to be $1.89 per share when they release Q4 earnings results on Tuesday, Feb 15.